The incidence of thyroid cancer in the United States, having plateaued in 2009 after a decades-long increase, has remained stable since then, despite efforts to control an ongoing overdiagnosis of the disease, new research shows. “Although the incidence of thyroid cancer has plateaued, it remains at peak levels, suggesting that overdiagnosis remains a crucial unresolved … Read more
New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment. However, a notably increased rate of thyroid cancer detections limited only to the first year after drug initiation — but … Read more
Patients with low-risk differentiated thyroid cancer show similar outcomes after 5 years regardless of whether they received radioactive iodine following total thyroidectomy, results from a randomized trial show, suggesting patients can be safely spared the additional radioiodine treatment, with some exceptions, including high-risk cases. “This is the first randomized, prospective trial showing that radioiodine is … Read more
In the largest study of its kind involving a diabetic population, the use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs shows no significantly increased risk for thyroid cancer, with the important caveat of the study’s relatively short follow-up period. “In this large multisite study utilizing data from 6 population-based databases, we found no … Read more